Zacks Research Expects Weaker Earnings for Cooper Companies

The Cooper Companies, Inc. (NASDAQ:COO) – Equities researchers at Zacks Research decreased their Q2 2025 earnings per share estimates for shares of Cooper Companies in a research note issued to investors on Thursday, March 27th. Zacks Research analyst I. Bandyopadhyay now expects that the medical device company will post earnings of $0.93 per share for the quarter, down from their previous estimate of $0.94. The consensus estimate for Cooper Companies’ current full-year earnings is $3.98 per share. Zacks Research also issued estimates for Cooper Companies’ Q3 2026 earnings at $1.16 EPS, Q4 2026 earnings at $1.20 EPS, Q1 2027 earnings at $1.10 EPS and FY2027 earnings at $4.85 EPS.

A number of other brokerages also recently weighed in on COO. Morgan Stanley decreased their target price on shares of Cooper Companies from $104.00 to $102.00 and set an “equal weight” rating for the company in a research note on Friday, December 6th. Wells Fargo & Company lifted their price objective on Cooper Companies from $115.00 to $118.00 and gave the company an “overweight” rating in a research note on Friday, December 6th. Needham & Company LLC reiterated a “hold” rating on shares of Cooper Companies in a research note on Friday, March 7th. StockNews.com cut Cooper Companies from a “buy” rating to a “hold” rating in a research note on Wednesday, December 11th. Finally, Piper Sandler reiterated an “overweight” rating and issued a $115.00 price target (down previously from $120.00) on shares of Cooper Companies in a research note on Friday, March 7th. Four investment analysts have rated the stock with a hold rating and seven have issued a buy rating to the company’s stock. According to MarketBeat.com, Cooper Companies presently has a consensus rating of “Moderate Buy” and an average price target of $110.25.

Cooper Companies Stock Down 3.7 %

NASDAQ:COO opened at $81.27 on Monday. Cooper Companies has a 1-year low of $77.05 and a 1-year high of $112.38. The company has a debt-to-equity ratio of 0.32, a current ratio of 1.91 and a quick ratio of 1.12. The firm’s 50-day moving average price is $88.87 and its 200-day moving average price is $96.83. The company has a market capitalization of $16.25 billion, a PE ratio of 41.68, a P/E/G ratio of 2.25 and a beta of 1.02.

Cooper Companies (NASDAQ:COO) last posted its quarterly earnings data on Thursday, March 6th. The medical device company reported $0.92 earnings per share (EPS) for the quarter, hitting analysts’ consensus estimates of $0.92. The business had revenue of $964.70 million during the quarter, compared to the consensus estimate of $981.25 million. Cooper Companies had a return on equity of 9.38% and a net margin of 10.07%.

Institutional Trading of Cooper Companies

Hedge funds have recently bought and sold shares of the company. Byrne Asset Management LLC purchased a new position in Cooper Companies in the fourth quarter worth about $33,000. OFI Invest Asset Management purchased a new position in shares of Cooper Companies during the 4th quarter worth $34,000. New Age Alpha Advisors LLC bought a new stake in shares of Cooper Companies during the 4th quarter valued at $38,000. Covestor Ltd increased its stake in shares of Cooper Companies by 35.5% in the 4th quarter. Covestor Ltd now owns 458 shares of the medical device company’s stock worth $42,000 after purchasing an additional 120 shares in the last quarter. Finally, West Financial Advisors LLC bought a new stake in Cooper Companies during the fourth quarter valued at about $49,000. Hedge funds and other institutional investors own 24.39% of the company’s stock.

Cooper Companies Company Profile

The Cooper Companies, Inc, together with its subsidiaries, develops, manufactures, and markets contact lens wearers. The company operates in two segments, CooperVision and CooperSurgical. The CooperVision segment provides spherical lense, including lenses that correct near and farsightedness; and toric and multifocal lenses comprising lenses correcting vision challenges, such as astigmatism, presbyopia, and myopia in the Americas, Europe, Middle East, Africa, and Asia Pacific.